Clinical Edge Journal Scan

Lower Prevalence of Psychotic Disorders in Patients with PsA


 

Key clinical point: Compared with the general population, the prevalence of psychotic disorders was significantly lower in patients with psoriatic arthritis (PsA), but a co-diagnosis of PsA and psychotic disorders was associated with an increased mortality rate, that too at a lower age.

Major finding: The prevalence of psychotic disorders was significantly lower in patients with PsA vs the general population (0.61% vs 0.72%; P = .006). Patients with PsA who did vs did not have psychotic disorders had an increased likelihood of death (9.3% vs 4.9%; P = .005) and significantly lower age at death (64.7 years vs 74.5 years; P < .001).

Study details: This cohort study included 449,392 patients with psoriasis and 47,825 patients with PsA.

Disclosures: The lead author Emilie Brenaut declared receiving a postdoctoral fellowship from the French Society of Dermatology and the Collège des Enseignants en Dermatologie de France as well as personal fees and nonfinancial support from various sources. The other authors reported no conflicts of interest.

Source: Brenaut E, Godin O, Leboyer M, et al. Association between psychotic disorders and psoriasis or psoriatic arthritis: Cohort study of French health insurance database. J Invest Dermatol. 2024 (Jan 19). doi: 10.1016/j.jid.2024.01.005 Source

Recommended Reading

Commentary: PsA in Women, February 2024
MDedge Rheumatology
Review Finds No Short-term MACE, VTE risk with JAK Inhibitors For Dermatoses
MDedge Rheumatology
Comorbidities and Disease Type Weigh Heavily in Pregnancy Outcomes of Immune-Mediated Inflammatory Diseases
MDedge Rheumatology
Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis
MDedge Rheumatology
Pretreatment Lab Testing for Chronic Skin Diseases Diverges From Guidelines
MDedge Rheumatology
Vascular Inflammation is Increased in Patients with PsA
MDedge Rheumatology
Neuropathic Pain May Increase Disease Burden in PsA
MDedge Rheumatology
Upadacitinib Offers Enthesitis Resolution in PsA
MDedge Rheumatology
Meta-analysis Confirms Promising Efficacy-Safety Profile of Risankizumab in PsA
MDedge Rheumatology
Tofacitinib Effective Across Multiple PsA Domains in The Real World
MDedge Rheumatology